• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Full U.S. Rollout Could Change The Case For Haemonetics Stock

    Simply Wall St·10/09/2026 07:50:43
    Listen to the news
    • Haemonetics expanded its non exclusive supply agreement with CSL Plasma, which now plans to deploy NexSys PCS devices with Persona PLUS technology and related disposables across all of its U.S. plasma collection centers by the end of 2027.
    • The move shifts CSL from a partial, undefined rollout to a full, timed conversion, increasing Haemonetics' visibility on multi year device and consumable demand from a key plasma collection customer.
    • The focus now turns to how Haemonetics' investment narrative could be reshaped by CSL's commitment to systemwide NexSys PCS deployment.
    Scan how Haemonetics' rebound with CSL compares to other healthcare equipment players by sizing up the hand picked list of solid balance sheet and fundamentals (25 results).

    Haemonetics Investment Narrative Recap

    For a shareholder in Haemonetics, the core belief is that its plasma, TEG hemostasis and vascular closure franchises can turn clinical adoption and recurring disposable usage into consistent cash generation, despite tariff headwinds and meaningful debt. CSL’s full NexSys rollout supports that plasma thesis and gives more visibility on equipment and consumables demand into 2027.

    The key near term catalyst now sits around execution on the CSL deployment and any updated financial framing on the November 2026 earnings call. The main risk is that margin pressure from tariffs, self insured medical costs or pricing competition limits the earnings benefit and slows deleveraging from roughly US$1.2b of borrowings.

    The announcement that CSL plans to equip all U.S. plasma centers with Haemonetics NexSys PCS devices and Persona PLUS by the end of 2027 is the clearest recent signal tied directly to those plasma catalysts. It ties real world rollout plans to the earlier narrative that Persona PLUS can lift plasma yields and support higher margin disposable volumes.

    That said, execution and contract structure still matter. The agreement is non exclusive, so plasma volumes and consumables share will depend on how reliably Haemonetics ships systems, manages service and keeps the technology compelling against rivals, while balancing the impact of tariffs and funding costs on what ultimately drops through to earnings.

    Haemonetics' current analyst narrative points to revenues of about $1.6b and earnings of $248.7 million by 2029, based on an assumed 6.1% yearly revenue growth rate and an earnings increase of roughly 2.6x from $96.3 million today.

    Uncover why Haemonetics' fair value indicates a 7% potential downside to its current price, leaving little room for error.

    NYSE:HAE 1-Year Stock Price Chart
    NYSE:HAE 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view emphasizes the CSL angle. Bullish analysts already saw Haemonetics as underappreciated, assuming revenue of about US$1.8b and earnings near US$280.5 million by 2029. You now have a much more optimistic plasma recapture story layered on top of that. Opinions clearly range widely, so treat this as a prompt to compare several narratives, not a final answer.

    Explore another Haemonetics fair value estimate, including one that suggests up to 48% upside from the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view based on your research.

    Looking for more investment ideas beyond Haemonetics?

    Once you have a view on Haemonetics, it can help to line it up against other opportunities that fit different goals, whether that is value, income, or balance sheet strength. The Simply Wall St Screener lets you do that quickly by filtering for companies that match the traits you care about most.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.